Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about interest in watching the Pelage PP405 presentation online, with mentions of hair loss treatments like finasteride. Users express frustration and humor about the topic, with one user noting finasteride caused discomfort.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

A user shared a positive 6-month update after a hair transplant with MCAN in Turkey, using the Sapphire FUE method with 4000 grafts from the back and side of the head. The user is pleased with the natural-looking hairline and new growth, recommending the clinic for its professionalism and support.

Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.

The user experienced significant hair regrowth after 2.5 years of using Minoxidil 5% and hormone replacement therapy (HRT) with Lupron, despite initial scalp irritation. Finasteride was ineffective for them.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The user is 10 days post-hair transplant, pleased with the results so far, and hopes for increased density. The procedure was done at Vanity Hospital in Istanbul, with around 3400-3750 grafts used.

The user has tried various treatments for hair loss, including finasteride, dutasteride, and oral minoxidil, but is considering a hair transplant due to insufficient progress. Some users suggest that the treatments have at least stabilized hair loss, and recommend consulting clinics for a potential hair transplant while continuing medication.

A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.

A user is using Minoxidil, finasteride, saw palmetto, and Minimalist RCP serum to address hair thinning, with some success but concerns about the long-term benefits of Minimalist. They plan to continue Minoxidil and finasteride for another year before considering a hair transplant.

The user successfully managed hair regrowth by using a combination of finasteride, dutasteride, minoxidil, and specific shampoos to treat seborrheic dermatitis. They emphasize the importance of maintaining a healthy scalp and are considering food intolerance tests to further address inflammation.

BPC-157 is debated for hair loss, with some claiming it helps, but most agree there's no solid evidence for hair regrowth. Finasteride is mentioned as a common treatment, but results vary.

User shared 15-month results using finasteride and minoxidil, showing no loss but minimal growth, considering a hair transplant. Replies suggest starting treatment earlier, continuing current treatment, or getting a transplant.

A 29-year-old male reports using 1.25mg finasteride daily and applying minoxidil twice daily to the temples for hair loss, noting modest progress over 13 months. He attributes rapid hair loss onset to creatine use and is considering a hair transplant in the future.

Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. The conversation humorously reflects on past hair loss solutions and the potential of hair cloning.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

A 22-year-old man experienced significant hair regrowth using a combination of biotin supplements, Hims topical finasteride + minoxidil solution, a microneedling pen, 0.5 mg dutasteride, and topical PP405 solution. Despite skepticism about PP405's effectiveness, he claims this regimen worked for him after previous treatments failed.

The user stopped using finasteride and minoxidil after a hair transplant, now only using coconut oil and serum, and is concerned about potential hair loss. Others advise continuing finasteride to prevent future hair loss, despite the user's doctor suggesting it's unnecessary.

The user shared progress after four months of using a topical treatment with 0.3% finasteride and 6% minoxidil from Hims, noting positive results and considering switching to oral medication for convenience. Other users discussed the effectiveness of minoxidil and finasteride, emphasizing that first-time users often see the best results, and shared personal experiences with hair regrowth and maintenance.

The user experienced significant hair regrowth after 8 months on hormone replacement therapy (HRT) without using minoxidil or finasteride. Previous use of dutasteride showed no results.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

An 18-year-old shares progress in hair regrowth after 1.5 months using a topical treatment with finasteride, ketoconazole, minoxidil, and biotin. They report significant hairline improvement and a decrease in sex drive as a side effect.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to maintain hair production and potentially increasing transplant yield. The conversation questions if this method is practiced in clinics or remains theoretical, and whether it relates to hair cloning or multiplication.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

The user switched from finasteride to dutasteride and is using minoxidil and RU58841 for hair loss treatment. They are satisfied with the progress and considering a hair transplant, despite some initial shedding after the medication change.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

The user experienced worsening hair loss despite using dutasteride tablets and is considering switching to dutasteride gel capsules due to concerns about tablet bioavailability. Another user mentioned that countries like Japan, Korea, and India use the tablet form, suggesting the form may not be the issue.